Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 50.5% in March

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large drop in short interest in March. As of March 31st, there was short interest totaling 20,598 shares, a drop of 50.5% from the March 15th total of 41,648 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily volume of 25,310 shares, the days-to-cover ratio is presently 0.8 days.

Xenetic Biosciences Stock Down 2.9%

Shares of XBIO opened at $3.06 on Friday. Xenetic Biosciences has a 52-week low of $1.90 and a 52-week high of $13.93. The company has a 50-day simple moving average of $2.60 and a 200-day simple moving average of $2.84. The company has a market capitalization of $7.01 million, a PE ratio of -1.92 and a beta of 2.19.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Thursday, March 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.30. Xenetic Biosciences had a negative net margin of 90.09% and a negative return on equity of 51.27%. The firm had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.69 million. On average, research analysts anticipate that Xenetic Biosciences will post -1.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.